Growth hormone treatment and risk of solid tumours: A statement from the Drugs and Therapeutics Committee of the European Society for Paediatric Endocrinology (ESPE)

Hormone Research

Volumn 60, Issue 2, 2003, Pages 103-104

  Juul, Anders ^a,g   Bernasconi, Sergio ^b   Carel, Jean Claude ^c   Clayton, Peter E ^d   Kiess, Wieland ^e   Schrama, Sabine DeMuinck Keizer ^f  

^a Univ Dept of Growth and Repro   (Denmark)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c INSERM   (France)

^d ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^e Department of Pediatrics ^*  (Germany)

^f SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^g Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C;

APOPTOSIS; AVASCULAR NECROSIS; BRAIN PSEUDOTUMOR; CANCER RISK; CELL PROLIFERATION; COLORECTAL CARCINOMA; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; FEMUR EPIPHYSIS; FLUID RETENTION; FRAGILITY FRACTURE; HEALTH SURVEY; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPOPITUITARISM; IATROGENIC DISEASE; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; LEUKEMIA; NEOPLASM; PRIORITY JOURNAL; SHORT SURVEY; SIDE EFFECT; SOLID TUMOR;

HUMAN GROWTH HORMONE; HUMANS; NEOPLASMS;

EID: 0041742294     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000071879     Document Type: Short Survey

References (18)

1. Critical evaluation of the safety of recombinant human growth hormone administration: Statement from the Growth Hormone Research Society. J Clin Endocrinol Metab 2001;86:1868-1870.
2. Swerdlow AJ, Higgins CD, Adlard P, Preece MA: Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: A cohort study. Lancet 2002;360:273-277.
3. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: Summary statement of the Growth Hormone Research Society Workshop on Adult Growth Hormone Deficiency. J Clin Endocrinol Metab 1998;83:379-381.
4. Juul A, Bernasconi S, Clayton P, Kiess W, DeMuinck-Keizer Schrama SMPF: European audit of current practise in diagnosis and treatment of childhood growth hormone deficiency. Horm Res 2002;58:233-241.
5. Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998;279:563-566.
6. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002;94:1099-1106.
7. Stattin P, Bylund A, Rinaldi S, et al: Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: A prospective study. J Natl Cancer Inst 2000;92:1910-1917.
8. Hankinson SE, Willett WC, Colditz GA, et al: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-1396.
9. Toniolo P, Bruning PF, Akhmedkhanov A, et al: Serum insulin-like growth factor-I and breast cancer. Int J Cancer 2000;88:828-832.
10. Lukanova A, Toniolo P, Akhmedkhanov A, et al: A prospective study of insulin-like growth factor-I, IGF-binding proteins-1, -2 and -3 and lung cancer risk in women. Int J Cancer 2001;92:888-892.
11. London SJ, Yuan JM, Travlos GS, et al: Insulin-like growth factor I, IGF-binding protein 3, and lung cancer risk in a prospective study of men in China. J Natl Cancer Inst 2002;94:749-754.
12. Giovannucci E, Pollak MN, Platz EA, et al: A prospective study of plasma insulin-like growth factor-1 and binding protein-3 and risk of colorectal neoplasia in women. Cancer Epidemiol Biomarkers Prev 2000;9:345-349.
13. Ma J, Pollak MN, Giovannucci E, et al: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-625.
14. Kaaks R, Toniolo P, Akhmedkhanov A, et al: Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000;92:1592-1600.
15. Probst-Hensch NM, Yuan JM, Stanczyk FZ, Gao YT, Ross RK, Yu MC: IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: Association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer 2001;85:1695-1699.
16. Garnero P, Sornay-Rendu E, Delmas PD: Low serum IGF-1 and occurrence of osteoporotic fractures in postmenopausal women. Lancet 2000;355:898-899.
17. Sandhu MS, Heald AH, Gibson JM, Cruickshank JK, Dunger DB, Wareham NJ: Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: A prospective observational study. Lancet 2002;359:1740-1745.
18. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jørgensen T: Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease. A population-based case-control study. Circulation 2002;106:939-944.